Cellectis S.A. (CLLS)

NASDAQ: CLLS · IEX Real-Time Price · USD
2.670
+0.170 (6.80%)
At close: Mar 27, 2024, 4:00 PM
2.700
+0.030 (1.12%)
Pre-market: Mar 28, 2024, 4:21 AM EDT

Company Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.

The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL.

The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products.

Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A.
Cellectis logo
Country France
Founded 1999
IPO Date Feb 7, 2007
Industry Biotechnology
Sector Healthcare
Employees 231
CEO Dr. Andre Choulika Ph.D.

Contact Details

Address:
8 Rue De La Croix Jarry
Paris, Lle-de-france, I0 75013
France
Phone 33181691600
Website cellectis.com

Stock Details

Ticker Symbol CLLS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001627281
CUSIP Number 15117K103
ISIN Number US15117K1034
SIC Code 2836

Key Executives

Name Position
Dr. Andre Choulika Ph.D. Co-Founder, Chief Executive Officer and Director
Dr. David j. d. Sourdive Ph.D. Deputy Chief Executive Officer, Executive Vice President of CMC and Manufacturing and Director
Dr. Bing C. Wang M.B.A., Ph.D. Chief Financial Officer
Valerie Cros Principal Financial Officer and Principal Accounting Officer
Jean Charles Epinat Chief Technological Officer
Dr. Philippe Duchateau Ph.D. Chief Scientific Officer
Stephan Reynier M.Sc. Chief Regulatory and Pharmaceutical Compliance Officer
Marie-Bleuenn Terrier General Counsel and Secretary of the Board of Directors
Pascalyne Wilson Director of Communications
Kyung Nam-Wortman Executive Vice President and Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 16, 2024 6-K Report of foreign issuer
Dec 22, 2023 6-K Report of foreign issuer
Dec 22, 2023 6-K Report of foreign issuer
Dec 5, 2023 6-K Report of foreign issuer
Dec 5, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 17, 2023 6-K Report of foreign issuer
Nov 17, 2023 6-K Report of foreign issuer
Nov 16, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership